title: Response to comment on Hempe et al. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care 2015;38:1067-1074.
authors.affiliation: Department of Pediatrics, Louisiana State University Health Sciences Center and Children's Hospital Research Institute for Children, New Orleans, LA jhempe@chnola-research.org.
authors.forename: James M
authors.initials: JM
authors.lastname: Hempe
authors.affiliation: Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA.
authors.forename: Shuqian
authors.initials: S
authors.lastname: Liu
authors.affiliation: Department of Biostatistics and Bioinformatics, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.
authors.forename: Leann
authors.initials: L
authors.lastname: Myers
authors.affiliation: Research Division of Biostatistics and Study Methodology, Children's National Medical Center, Washington, DC.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: McCarter
authors.affiliation: Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.
authors.forename: John B
authors.initials: JB
authors.lastname: Buse
authors.affiliation: Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA.
authors.forename: Vivian
authors.initials: V
authors.lastname: Fonseca
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control*; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008297:Male
chemical_list: D007004:Hypoglycemic Agents